A detailed history of Mitsubishi Ufj Trust & Banking Corp transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Mitsubishi Ufj Trust & Banking Corp holds 209,908 shares of BMRN stock, worth $13.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
209,908
Previous 184,009 14.07%
Holding current value
$13.3 Million
Previous $15.1 Million 2.61%
% of portfolio
0.03%
Previous 0.04%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$69.02 - $93.84 $1.79 Million - $2.43 Million
25,899 Added 14.07%
209,908 $14.8 Million
Q2 2024

Aug 08, 2024

BUY
$74.43 - $92.22 $358,157 - $443,762
4,812 Added 2.69%
184,009 $15.1 Million
Q1 2024

May 10, 2024

SELL
$83.81 - $99.0 $668,971 - $790,218
-7,982 Reduced 4.26%
179,197 $15.7 Million
Q4 2023

Feb 09, 2024

BUY
$76.22 - $98.51 $609,683 - $787,981
7,999 Added 4.46%
187,179 $18 Million
Q3 2023

Nov 09, 2023

SELL
$85.07 - $94.48 $306,847 - $340,789
-3,607 Reduced 1.97%
179,180 $15.9 Million
Q2 2023

Aug 08, 2023

BUY
$86.68 - $100.3 $161,744 - $187,159
1,866 Added 1.03%
182,787 $15.8 Million
Q1 2023

May 10, 2023

BUY
$87.74 - $117.27 $222,947 - $297,983
2,541 Added 1.42%
180,921 $17.6 Million
Q4 2022

Feb 10, 2023

BUY
$80.93 - $108.63 $32,614 - $43,777
403 Added 0.23%
178,380 $18.5 Million
Q3 2022

Nov 10, 2022

SELL
$82.16 - $96.94 $3.39 Million - $4 Million
-41,295 Reduced 18.83%
177,977 $15.1 Million
Q2 2022

Aug 09, 2022

BUY
$71.48 - $86.85 $2.12 Million - $2.57 Million
29,638 Added 15.63%
219,272 $18.2 Million
Q1 2022

May 12, 2022

SELL
$74.28 - $92.69 $1.09 Million - $1.36 Million
-14,698 Reduced 7.19%
189,634 $14.6 Million
Q4 2021

Feb 09, 2022

BUY
$71.72 - $91.47 $6.59 Million - $8.4 Million
91,876 Added 81.7%
204,332 $18.1 Million
Q3 2021

Nov 12, 2021

BUY
$74.77 - $85.47 $196,794 - $224,957
2,632 Added 2.4%
112,456 $8.69 Million
Q2 2021

Aug 12, 2021

SELL
$75.51 - $84.79 $884,977 - $993,738
-11,720 Reduced 9.64%
109,824 $9.16 Million
Q1 2021

May 12, 2021

SELL
$74.73 - $90.69 $1.64 Million - $1.99 Million
-21,979 Reduced 15.31%
121,544 $9.2 Million
Q4 2020

Feb 12, 2021

BUY
$72.61 - $90.2 $493,384 - $612,909
6,795 Added 4.97%
143,523 $12.6 Million
Q3 2020

Nov 12, 2020

SELL
$71.87 - $131.03 $254,204 - $463,453
-3,537 Reduced 2.52%
136,728 $10.4 Million
Q2 2020

Sep 11, 2020

SELL
$79.55 - $124.22 $1.1 Million - $1.72 Million
-13,853 Reduced 8.99%
140,265 $17.3 Million
Q2 2020

Aug 13, 2020

BUY
$79.55 - $124.22 $893,426 - $1.4 Million
11,231 Added 7.86%
154,118 $17.3 Million
Q1 2020

May 13, 2020

BUY
$71.37 - $96.85 $598,794 - $812,571
8,390 Added 6.24%
142,887 $12.1 Million
Q4 2019

Feb 14, 2020

SELL
$64.27 - $86.37 $78,666 - $105,716
-1,224 Reduced 0.9%
134,497 $11.4 Million
Q3 2019

Nov 12, 2019

SELL
$67.4 - $85.11 $229,362 - $289,629
-3,403 Reduced 2.45%
135,721 $9.27 Million
Q2 2019

Aug 07, 2019

BUY
$80.35 - $93.9 $430,354 - $502,928
5,356 Added 4.0%
139,124 $11.7 Million
Q1 2019

May 13, 2019

BUY
$84.2 - $98.62 $27,196 - $31,854
323 Added 0.24%
133,768 $11.7 Million
Q4 2018

Feb 12, 2019

BUY
$80.14 - $106.07 $163,966 - $217,019
2,046 Added 1.56%
133,445 $11.4 Million
Q3 2018

Nov 13, 2018

SELL
$93.92 - $105.72 $21 Million - $23.7 Million
-223,991 Reduced 63.03%
131,399 $12.7 Million
Q2 2018

Aug 10, 2018

BUY
$76.01 - $99.03 $186,072 - $242,425
2,448 Added 0.69%
355,390 $33.5 Million
Q1 2018

May 11, 2018

BUY
$77.67 - $92.63 $72,543 - $86,516
934 Added 0.27%
352,942 $28.6 Million
Q4 2017

Feb 09, 2018

BUY
$80.76 - $95.13 $5,330 - $6,278
66 Added 0.02%
352,008 $31.4 Million
Q3 2017

Nov 13, 2017

BUY
$80.6 - $94.95 $28.4 Million - $33.4 Million
351,942
351,942 $32.8 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Mitsubishi Ufj Trust & Banking Corp Portfolio

Follow Mitsubishi Ufj Trust & Banking Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Trust & Banking Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Trust & Banking Corp with notifications on news.